A new Cochrane review showed SSRIs and SNRIs outperform placebo for GAD with similar dropout rates, but questions remain ...

They can help you come up with a schedule to help you wean yourself off the drug with minimum symptoms. Regardless of the type of antidepressant you take, the most common side effects include ...

A new review from the Cochrane Database of Systematic Reviews confirms that antidepressants can effectively reduce symptoms ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.

During his Senate confirmation hearing to serve as Health and Human Services Secretary, Robert F. Kennedy, Jr. suggested ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The approval, which followed FDA priority review of a supplemental new drug application submitted in July 2024, stemmed from results of a randomized, double-blind, multicenter, placebo-controlled ...